Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference [Yahoo! Finance]
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference